Ajanta Pharma Limited announced its financial results for the second quarter of FY26, reporting solid performance across key business segments, particularly in branded generics and international markets. The company also declared an interim dividend of ₹28 per share for FY26.
Financial Performance Overview
Ajanta Pharma’s branded generics business outperformed the Indian Pharmaceutical Market (IPM), driven by strong growth in ophthalmology and dermatology segments, surpassing industry growth by 32%.
| Financial Metric (₹ crore) | Q2 FY26 | Q2 FY25 | YoY Change |
| Revenue from Operations | 1,354 | 1,187 | +14% |
| EBITDA | 328 | 312 | +5% |
| Net Profit | 260 | 216 | +20% |
Segment-Wise Highlights
For the quarter ended September 30, 2025, Ajanta Pharma posted a 20% rise in consolidated net profit and a 14% increase in total revenue.
| Segment | Q2 FY26 Revenue (₹ crore) | YoY Growth |
| India – Branded Generics | 432 | +12% |
| US – Generics | 344 | +48% |
| Consolidated Revenue (H1 FY26) | 2,656 | +14% (YoY) |
| Net Profit (H1 FY26) | 516 | +12% (YoY) |
Dividend Declaration
The Board of Directors has approved the first interim dividend for FY26 at ₹28 per equity share (face value ₹2 each), amounting to a total payout of ₹349.82 crore.
- Record Date: November 10, 2025
- Payment Date: On or after November 20, 2025
Shareholders holding Ajanta Pharma shares as of the record date will be eligible for the dividend.
Summary:
Ajanta Pharma reported a 20% year-on-year rise in net profit to ₹260 crore for Q2 FY26, supported by strong performance in branded and US generics. Revenue grew 14% to ₹1,354 crore. The company declared an interim dividend of ₹28 per share, reinforcing its focus on shareholder returns alongside consistent business growth.
Disclaimer:
This article is intended solely for educational and informational purposes. The securities or companies mentioned are provided as examples and should not be considered as recommendations. Nothing contained herein constitutes personal financial advice or investment recommendations. Readers are advised to conduct their own research and consult a qualified financial advisor before making any investment decisions.
Investments in securities markets are subject to market risks. Please read all related documents carefully before investing.